Company focused on medical research and development for tissue-level regeneration
Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. Stemming from foundational discoveries in Wnt pathway modulation, Biosplice has elucidated novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative splicing. Alternative splicing is an essential biological mechanism that regulates the diversification of proteins in a cell, which, in turn, determines cell type and function. Biosplice’s target class governs the selection of tissue-specific mRNA splice sites, making them attractive, druggable targets within the cellular “command and control” center.
Biosplice’s drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer’s disease to other degenerative conditions.
Visit website: https://www.biosplice.com/default.aspx
People at Biosplice
Longevity.Technology looks at 12 key companies running age-related disease clinical trials in 2021
Longevity Technology - 25-Feb-2022
Approaches include senotherapeutics, stem cells and mitochondria. Eye disease is a common first target.Read more...
Biosplice dosed first patient with cirtuvivint in phase 1 clinical trial
Global News - 17-Nov-2021
Evaluates the safety and anti-tumor efficacy of oral cirtuvivint in cancer patientsRead more...
Developmental stages of anti-ageing treatments
Next Big Future - 09-Jun-2019
Two anti-ageing treatments in phase 3 clinical trials and four in phase 2 clinical trialsRead more...